Stable, compounded bedaquiline suspensions to support practical implementation of pediatric dosing in the field
The International Journal of Tuberculosis and Lung Disease · 01.03.2023 · 27 (3) · 189-194
DOI: 10.5588/ijtld.22.0440 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, erschienen am 01.03.2023. Verfasst von R Taneja und 10 weiteren Autor:innen. Beteiligte Einrichtung: Global Alliance for TB Drug Development (TB Alliance), New York, NY, USA. Hauptthemen laut MEDLINE: Antitubercular Agents, Diarylquinolines, Drug Compounding, Tuberculosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Bedaquiline (BDQ) tablets are indicated as part of a combination regimen for the treatment of multidrug-resistant TB in adults, adolescents and children. A dispersible tablet formulation is now approved but is not currently available in all settings. The aim of this study was to develop stable extemporaneous liquid formulations of BDQ that can be stored at room temperature or 30°C for several weeks, to support pragmatic pediatric dosing in the field and reduce wastage. METHODS: BDQ tablets were suspended in simple syrup and a sugar-free vehicle. Each 20 mg/mL formulation was stored at room temperature or 30°C for 30 days in amber dispensing bottles. Appearance, BDQ potency, pH and microbial counts were determined on Days 0, 15 and 30. RESULTS: The BDQ potency in both formulations remained at 98–101% of the theoretical concentration for 30 days. The appearance, pH and microbial count of sugar-free formulation did not change during the 30-day storage. The simple syrup formulation was stable for 15 days as microbial growth was observed on Day 30. CONCLUSIONS: BDQ may be prepared in syrup or sugar-free suspensions: syrup suspensions can be stored for 15 days at room temperature and 30C, whereas sugar-free suspensions can be stored for 30 days at room temperature and 30C. This information will support practical BDQ dosing for children in the field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Global Alliance for TB Drug Development (TB Alliance), New York, NY, USA.
- Institute of Therapeutic Innovations and Outcomes, Colleges of Pharmacy and Medicine, The Ohio State University, Columbus, OH, USA.
- JSAS Services Inc Tucson, AZ, USA.
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
- Metro TB Complex, Department of Health, Pretoria, South Africa.
- Institute for Safe Medication Practices (ISMP), Plymouth Meeting, PA, USA.
Zitieren
APA
Taneja, R., Nahata, M. C., Scarim, J., Pande, P. G., Scarim, A., Hoddinott, G., Fourie, C. L., Jew, R. K., Schaaf, H. S., Garcia-Prats, A. J., & Hesseling, A. C. (2023). Stable, compounded bedaquiline suspensions to support practical implementation of pediatric dosing in the field. The International Journal of Tuberculosis and Lung Disease, 27(3), 189-194. https://doi.org/10.5588/ijtld.22.0440
Vancouver
Taneja R, Nahata MC, Scarim J, Pande PG, Scarim A, Hoddinott G, et al. Stable, compounded bedaquiline suspensions to support practical implementation of pediatric dosing in the field. The International Journal of Tuberculosis and Lung Disease. 2023;27(3):189-194. doi:10.5588/ijtld.22.0440
BibTeX
@article{Taneja2023,
author = {Taneja, R and Nahata, M C and Scarim, J and Pande, P G and Scarim, A and Hoddinott, G and Fourie, C L and Jew, R K and Schaaf, H S and Garcia-Prats, A J and Hesseling, A C},
title = {Stable, compounded bedaquiline suspensions to support practical implementation of pediatric dosing in the field},
journal = {The International Journal of Tuberculosis and Lung Disease},
year = {2023},
volume = {27},
number = {3},
pages = {189--194},
doi = {10.5588/ijtld.22.0440}
}
EUVIMED